Need help finding what you are looking for?
Contact Us
PUBLISHER: GlobalData | PRODUCT CODE: 1772151
PUBLISHER: GlobalData | PRODUCT CODE: 1772151
Multiple Sclerosis - Seven-Market Drug Forecast and Market Analysis
PUBLISHED:
PAGES: 112 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
This report covers the 7 major markets and provides an Excel-based forecast model for the Multiple Sclerosis (MS) market through 2034.
GlobalData estimated that the PD market was $22.0 billion across the 7MM in 2024. By the end of the forecast period in 2033, sales across these markets will reach $25.9 billion, increasing at a compound annual growth rate (CAGR) of 1.7%.
The major drivers of growth in the PD market will be the launch of new disease modifying therapies (DMTs) with new mechanisms of action (MOAs) across the 7MM that target MS disease progression which will also increase treatment rates during the forecast period, and a trend towards the use of high-efficacy treatments such as anti-CD20 monoclonal antibodies (mAbs), which have high annual costs of therapy and high patient compliance rates.
Brand erosion due to the emergence of biosimilars and generic small molecules will hamper the future growth of the global MS market.
Scope
- Overview of Multiple Sclerosis, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized Multiple Sclerosis therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the Multiple Sclerosis therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for Multiple Sclerosis treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global Multiple Sclerosis therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Multiple Sclerosis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Multiple Sclerosis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Product Code: GDHC319PIDR-7M
Table of Contents
Table of Contents
List of Tables
List of Figures
- About GlobalData
1 Multiple Sclerosis: Executive Summary
- 1.1 The MS market will grow to $25.9 billion
- 1.2 Current players are to remain leaders in the MS market in 2034
- 1.3 Opportunities remain to fulfill key unmet needs
- 1.4 Novel late-stage pipeline drugs will be a key driver of growth
- 1.5 What do physicians think?
2 Introduction
- 2.1 Catalyst
- 2.2 Related reports
- 2.3 Upcoming reports
3 Disease Overview
- 3.1 Etiology and pathophysiology
- 3.1.1 Etiology
- 3.1.2 Pathophysiology
- 3.2 Classification or staging systems
- 3.2.1 Radiologically isolated syndrome and clinically isolated syndrome
- 3.2.2 Relapsing-remitting MS
- 3.2.3 Secondary progressive MS
- 3.2.4 Primary progressive MS
4 Epidemiology
- 4.1 Disease background
- 4.2 Risk factors and comorbidities
- 4.3 Global and historical trends
- 4.4 7MM forecast methodology
- 4.4.1 Sources
- 4.4.2 Forecast assumptions and methods
- 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of MS
- 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of MS by type
- 4.5 Epidemiological forecast for MS (2024-34)
- 4.5.1 Diagnosed prevalent cases of MS
- 4.5.2 Age-specific diagnosed prevalent cases of MS
- 4.5.3 Sex-specific diagnosed prevalent cases of MS
- 4.5.4 Diagnosed prevalent cases of MS by type
- 4.6 Discussion
- 4.6.1 Epidemiological forecast insight
- 4.6.2 Limitations of the analysis
- 4.6.3 Strengths of the analysis
5 Disease Management
- 5.1 Diagnosis overview
- 5.2 Treatment overview
6 Current Treatment Options
- 6.1 Overview
7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 A curative therapy
- 7.3 Preventing disease progression and addressing progressive forms of MS
- 7.4 Safety and tolerability of DMTs
- 7.5 Biomarkers for MS progression and treatment response
8 R&D Strategies
- 8.1 Overview
- 8.1.1 Reformulations and optimizing delivery systems
- 8.1.2 Bruton's tyrosine kinase inhibitors
- 8.1.3 Cell and gene therapies in MS
- 8.2 Clinical trials design
- 8.2.1 Primary endpoints
- 8.2.2 Active comparator versus placebo
- 8.2.3 Inclusion criteria - age
9 Pipeline Assessment
- 9.1 Overview
- 9.2 Promising drugs in clinical development
10 Pipeline Valuation Analysis
- 10.1 Overview
- 10.2 Competitive assessment
11 Current and Future Players
- 11.1 Overview
- 11.2 Deal-making trends
12 Market Outlook
- 12.1 Global markets
- 12.1.1 Forecast
- 12.1.2 Drivers and barriers - global issues
- 12.2 US
- 12.2.1 Forecast
- 12.2.2 Key events
- 12.2.3 Drivers and barriers
- 12.3 5EU
- 12.3.1 Forecast
- 12.3.2 Key events
- 12.3.3 Drivers and barriers
- 12.4 Japan
- 12.4.1 Forecast
- 12.4.2 Key events
- 12.4.3 Drivers and barriers
13 Appendix
- 13.1 Bibliography
- 13.2 Abbreviations
- 13.3 Methodology
- 13.3.1 Forecasting methodology
- 13.4 Primary research - KOLs interviewed for this report
- 13.4.1 KOLs
- 13.5 Primary research - prescriber survey
- 13.6 About the Authors
- 13.6.1 Analyst
- 13.6.2 Therapy Area Director
- 13.6.3 Epidemiologist
- 13.6.4 Managing Epidemiologist
- 13.6.5 Vice President of Disease Intelligence and Epidemiology
- 13.6.6 Global Head of Pharma Research, Analysis and Competitive Intelligence
- 13.7 Contact Us
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.